

## Drug Monograph

Drug Name: **Ayvakit™ (avapritinib) Tablets**  
 Drug Class: **Antineoplastic Agent, Tyrosine Kinase Inhibitor**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**                       **Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Ayvakit is available as an oral tablet containing 100 mg, 200 mg or 300 mg avapritinib.

**Manufacturer:** Manufactured for: Blueprint Medicines Corporation, Cambridge, MA 02139.

**Indications:** Ayvakit is indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

**Costs:** \$1,0666.67 per tablet of Ayvakit Wholesale Acquisition Cost

**Summary of Findings:** The MO Healthnet Division recommends adding this drug to the current 15-day quantity limitation fiscal edit.

**Status Recommendation:**       Fiscal Edit                       PA Required  
     Open Access                       PDL

**Type of PA Criteria:**               Appropriate Indications               Non-Preferred  
     No PA Required                       Preferred

Prepared by: Carrie Gatzke, PharmD, CSP  
 Date: March 29, 2020